Prostate-specific antigen-based screening for prostate cancer: A systematic review to inform an American Cancer Society guideline
In brief
PSA screening detects more low-risk cancers but reduces metastatic disease
A review of 29 publications found that PSA screening increased detection of low-risk prostate cancer while reducing advanced disease at diagnosis and the cumulative incidence of metastases. Some trials also found fewer prostate cancer deaths, but results varied with screening methods and participant characteristics. Overdiagnosis, false positives, biopsy complications, and treatment harms remain important trade-offs.
- Journal
- Cancer (Q1)
- Published
- 15 November 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Jessica C Griffin, Rita L Shiau, Clarissa A B Troutman, Alanna Welsh, Emily Edwards, Ibironke A Ajayi, et al.
- PMID
- 43018378
- DOI
- 10.1002/cncr.70660
Why clinicians should know about it
- Picked for Public Health, Environmental and Occupational Health (top studies of the week, 15 November 2026): Systematic review of population screening benefits and harms
- Picked for Epidemiology (top studies of the week, 15 November 2026): Screening review weighs mortality benefit, overdiagnosis, and harms
Abstract
The purpose of this systematic review was to identify and synthesize the evidence on the benefits and harms of prostate-specific antigen (PSA)-based screening for prostate cancer to inform the American Cancer Society's updated guideline. PubMed and the Cochrane Central Register of Controlled Trials were searched for published and gray literature through December 4, 2023, and updated through October 29, 2025, which allowed for approximately 3 months of overlap with searches conducted for the previous guideline. Eligible studies included randomized and nonrandomized comparisons of PSA-based screening strategies to no screening or other screening strategies. Low- and medium-risk of bias systematic reviews were included, and their findings were supplemented with studies published after the systematic review. One investigator abstracted study data, and a second confirmed. Two investigators independently assessed the risk of bias and strength of evidence, and discrepancies were resolved by consensus. Twenty-nine publications were included: two publications from a 2018 systematic review of PLCO, CAP, and ERSPC; 23 subsequent publications from six trials (PLCO, CAP, ERSPC, Göteborg-1, Rotterdam Pilot 1, and ProScreen); and four observational studies. PSA-based screening was associated with increased detection of low-risk prostate cancer, reduced incidence of advanced or metastatic disease at diagnosis, and reduced cumulative incidence of metastatic disease. Screening was associated with a reduction in prostate cancer-specific mortality in some trials, although findings were inconsistent and likely depended on screening protocols, PSA thresholds, participant characteristics, and other factors. Harms of screening included overdiagnosis, false-positive test results, biopsy-related complications, and downstream treatment harms.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.